A Letter to the Editor published in this week’s issue of the New England Journal of Medicine has, yet again, pointed out that the US-based PCLO trial was badly flawed and was never, in fact, a trial of screening against no screening. The “New” Prostate Cancer InfoLink is not at all sure what the point […]![]()
